6-Fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4H-[1,3]thiazolo[3,2-a]quinoline-3-carboxylic acid is supplied as a free base with an IUPAC designation that delineates the thiazolo[4,5-b]quinolone scaffold characteristic of the active metabolite of prulifloxacin. The material is isolated as a microcrystalline, off-white powder with a molecular weight of
361.39 g mol⁻¹ and an experimentally determined logD (pH
7.4) of
−0.43. Its pharmaceutical relevance is anchored in the role of ulifloxacin as the direct inhibitor of bacterial DNA gyrase and topoisomerase IV, a function that separates it from the largely inert lipophilic prodrug that was commercialized under the trade name Quisnon in Japan and Italy. High-resolution mass spectrometry on the free base typically returns an [M+H]⁺ at
362.1178 m/z (calculated
362.1180 m/z for C₁₇H₁₇FN₃O₃S), and the fragmentation pattern under collision-induced dissociation at
20 eV is dominated by neutral loss of CO₂ (
44 Da) and subsequent piperazine ring scission. Because the thiazole ring introduces a sulfur atom at position 9a in the quinolone core, the UV absorption spectrum shows a characteristic bathochromic shift of the major λmax to
282 nm, with a secondary shoulder at
315 nm that is absent in the simple quinoline-3-carboxylic acid fluoroquinolones such as ciprofloxacin or norfloxacin. This spectral signature enables rapid photodiode array identification during HPLC peak purity analysis when the compound is co-chromatographed with process-related impurities in prulifloxacin drug substance batches.
Pharmacopoeial Purity Requirements and Certificate of Analysis Parameters
The product is released according to specifications derived from the ICH Q6A decision tree for a chemical reference standard intended for use in analytical procedures for prulifloxacin bulk drug substance. A typical lot analysis includes a chromatographic purity of
≥99.2 area-% by HPLC using a Kromasil C18 column (
250 × 4.6 mm,
5 µm particle size) with a mobile phase consisting of phosphate buffer (pH
2.5) and acetonitrile in a gradient from
10% to
40% acetonitrile over
20 minutes at
1.0 mL min⁻¹. Detection is at
282 nm. Under these conditions, the retention time of the main peak is
14.3 ± 0.3 minutes, and any individual impurity does not exceed
0.15 area-%. Identity confirmation is achieved by Fourier transform infrared spectroscopy using a diamond ATR accessory; the characteristic carbonyl stretching vibration at
1624 cm⁻¹ (4-oxo group) and the asymmetric carboxylate stretch at
1728 cm⁻¹ are required to match the reference spectrum stored in the batch-specific electronic record.
1H-NMR in DMSO‑d₆ at
400 MHz must display the diagnostic quartet for the C-2 thiazole proton at δ
7.91 ppm (J =
1.9 Hz) and the multiplet integrating to four protons for the piperazine N‑(CH₂)₂ region at δ
3.28–3.34 ppm. Water content by Karl Fischer coulometry is controlled to
≤0.5% w/w, and residual solvents are monitored against the limits of USP <467> for Class 2 solvents, with N,N-dimethylformamide (DMF) restricted to
≤880 ppm when DMF is used as the final recrystallization medium.
A reproduction of the typical batch-to-batch specification parameters is provided in Table
1. Production-scale purification at the multigram level has been performed using medium-pressure liquid chromatography with a Biotage Sfär C18 D Duo column, and the eluate is concentrated on a rotary evaporator with a bath temperature not exceeding
35 °C to avoid thermal degradation. After lyophilization, residual piperazine content is assayed by ion chromatography, and values above
0.10% w/w trigger an additional trituration step with absolute ethanol at
5 °C; this step incurs approximately
10–12% mass loss and is a recognized bottleneck in kilogram-scale campaigns.
Table 1. Representative release specification for 6-fluoro-1-methyl-4-oxo-7-(1-piperazinyl)-4H-[1,3]thiazolo[3,2-a]quinoline-3-carboxylic acid (ulifloxacin free base) intended as an analytical reference standard.
| Parameter | Acceptance Criterion | Test Method |
|---|
| Appearance | Off-white to pale yellow powder | Visual (Ph. Eur. 2.2.2) |
| Purity (HPLC) | ≥99.0 area-% | In-house LC-UV, λ = 282 nm |
| Water content | ≤0.5% w/w | KF coulometry (Ph. Eur. 2.5.32) |
| Residual piperazine | ≤0.15% w/w | Ion chromatography with conductivity detection |
| Identity | IR spectrum concordant with reference | ATR-FTIR, 4000–400 cm⁻¹ |
| Assay (anhydrous basis) | 98.0–102.0% | Potentiometric titration with 0.1 N HClO₄ |
| Residual DMF | ≤880 ppm | Headspace GC-FID per USP <467> |
How does the thiazoloquinolone core alter photostability compared to naphthyridones?
Ulifloxacin, when exposed to a xenon arc lamp per the testing conditions of ICH Q1B (Option 2), undergoes a primary photodegradation pathway that differs mechanistically from the defluorination and oxidative ring opening observed for enoxacin or the N-oxide formation seen with ciprofloxacin. The thiazole ring fusion in the 9a position creates an extended conjugated system that red-shifts the absorption into the UVA region. Photolytic exposure at
200 W·h·m⁻² generates a decarboxylated photoproduct with a molecular mass shift of
−44 Da, which is detected by LC-MS as a single major impurity at relative retention time
0.78. The quantum yield for photodegradation in pH
7.0 phosphate buffer has been reported as
0.023 in peer-reviewed studies, which is approximately half of the yield determined for ofloxacin under identical radiant exposure. This relative photostability reduces the required masking of the reference standard during open-lab handling, though storage in amber glass vials under nitrogen headspace remains mandatory. When the compound is integrated into a forced degradation study of prulifloxacin tablets, the concentration of free ulifloxacin after exposure to
1.2 million lux·h of visible light and
200 W·h·m⁻² of UV radiation increases by
3.7–4.2% due to hydrolytic activation of residual prodrug rather than ulifloxacin decay. This behavior is routinely exploited during the validation of stability-indicating HPLC methods per ICH Q2(R1), where ulifloxacin serves as the primary degradant marker.
Synthetic Route Bottlenecks in the Final Piperazination Step
The 7-position piperazination of 6,7-difluoro-1-methyl-4-oxo-4H-[1,3]thiazolo[3,2-a]quinoline-3-carboxylic acid (the chloro- or fluoro-precursor) is carried out in acetonitrile or dimethyl sulfoxide at
80–85 °C with an excess of anhydrous piperazine (
3.0–3.5 eq). In a
50 L glass-lined reactor operated at pilot scale, the addition rate of the piperazine solution must not exceed
0.15 molar equivalents per hour to avoid a thermal run-up that pushes the internal temperature above
90 °C. When this threshold is breached, a brown-colored bis-adduct impurity forms at
0.8–1.2 area-%, and its removal by recrystallization from N-methylpyrrolidone/water (
3:1 v/v) reduces the overall yield to
58–62%, compared to
74–76% for a temperature-controlled addition. The reaction mass is further complicated by the limited solubility of the free base ulifloxacin in most Class 3 solvents; the crude product precipitates directly from the reaction mixture upon cooling to
2–5 °C, and a granulation hold of
4 hours is required to achieve a filterable particle size
D₅₀ above
25 µm. Filtration through a 0.5-µm cloth on a centrifuge with a basket speed ramped to
800 rpm is necessary, yet throughput remains constrained to approximately
1.3 kg of dry cake per batch in a
20-inch centrifuge basket. For campaigns requiring more than
5 kg of product, multiple parallel batches are executed, and inter-batch variance in residual piperazine has been correlated with the relative humidity in the reactor headspace during unloading.
When residual piperazine content exceeds 0.15% during final crystallization
Residual piperazine above
0.15% w/w in the final recrystallized product is not reduced simply by prolonged vacuum drying at
40 °C because piperazine forms a stable hemihydrate salt with the carboxylic acid group of ulifloxacin. This salt exhibits a differential scanning calorimetry endotherm at
138 °C (onset) that broadens the melting endotherm of the free base, normally observed at
216–218 °C. Batch records from a series of
15 production campaigns in a GMP facility indicate that the residual piperazine level can be driven below
0.10% only by reslurrying the crude filter cake in absolute ethanol at
60 °C for
1 hour followed by controlled cooling to
0 °C at a rate of
0.5 °C/min. The wash requires a minimum solvent-to-cake ratio of
5:1 (v/w), and the ethanolic mother liquor must be analyzed by ion chromatography before discharge, because piperazine concentrations exceeding
25 mg/L are subject to local effluent restrictions in some manufacturing jurisdictions. The operation adds approximately
8 hours to the overall cycle time and reduces the net yield by an additional
6–8%. In a subset of batches where the relative humidity in the drying suite exceeded
65%, post-slurry handling resulted in re-adsorption of atmospheric moisture sufficient to raise the water content to
1.1% within
90 minutes. This hygroscopicity imposes the requirement for immediate double-bagging with desiccant sachets in a glovebox flushed with nitrogen (
relative humidity <5%).
As a reference marker in bioequivalence studies, the compound is used in the preparation of working standard solutions at concentrations of
0.1–10 µg mL⁻¹ in
50:50 methanol:water containing
0.1% formic acid, which are stable for
48 hours at
4 °C when protected from light. An internal standard such as enrofloxacin-d₅ is spiked at
1 µg mL⁻¹, and the chromatographic system is qualified for system precision by ensuring that the area ratio of ulifloxacin to internal standard in six consecutive injections does not exceed an RSD of
2.0%. These solutions are the foundation for liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays validated over a linearity range of
0.05–50 ng mL⁻¹ in human plasma, which have been used to support the pharmacokinetic profiling of prulifloxacin generic formulations against the innovator product.
Table 2. Comparative structural and microbiological parameters distinguishing ulifloxacin from representative fluoroquinolones.
| Compound | Core Scaffold | C-7 Substituent | logD (pH 7.4) | MIC₉₀ E. coli ATCC 25922 | MIC₉₀ S. pneumoniae ATCC 49619 |
|---|
| Ulifloxacin | Thiazolo[3,2-a]quinolone | Piperazin-1-yl | −0.43 | 0.03 mg L⁻¹ | 0.25 mg L⁻¹ |
| Ciprofloxacin | Quinolone | Piperazin-1-yl | −1.10 | 0.015 mg L⁻¹ | 1.0 mg L⁻¹ |
| Levofloxacin | Tricyclic benzoxazine | 4-Methylpiperazin-1-yl | −0.51 | 0.03 mg L⁻¹ | 0.5 mg L⁻¹ |
| Moxifloxacin | 8-Methoxy quinolone | Diazabicyclo[3.3.0]octane | −0.18 | 0.06 mg L⁻¹ | 0.12 mg L⁻¹ |
MIC values reflect broth microdilution per CLSI M07-A11; logD determined by shake-flask method.
Direct administration of ulifloxacin is not pursued in clinical practice; the pharmacokinetic advantage of the prulifloxacin prodrug arises from the complete masking of the carboxylic acid as a diphenylmethyl ester, which elevates the oral absorption from approximately
22% (for the free acid) to over
85% in the fed state. Published data from crossover studies in healthy volunteers indicate that the peak plasma concentration of ulifloxacin following a
600 mg oral dose of prulifloxacin reaches
2.1–2.4 µg mL⁻¹ at T
max between
1.5–2.0 hours. The unbound fraction in human plasma is
42–46%, which is higher than that of ciprofloxacin (approximately
20–30%), a factor attributed to the lower affinity of ulifloxacin for α₁-acid glycoprotein.
